Albert Bourla (Photo by Steven Ferdman/Getty Images)
Pfizer fields a CRL for a $295M rare disease play, giving rival a big head start
Pfizer won’t be adding a new rare disease drug to the franchise club — for now, anyway.
The pharma giant put out word that their FDA …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
